investor.arbutusbio.com investor.arbutusbio.com

investor.arbutusbio.com

Arbutus Biopharma - Investor Relations

The Baruch S. Blumberg Institute. Surface Antigen Secretion Inhibitors. Oncology, Anti-virals and Metabolic Programs. RNAi Collaborators and Partners. HBV Collaborators and Partners. Arbutus Biopharma is a publicly-traded ( NASDAQ:TKMR. In addition to our HBV Assets. We are developing a pipeline of Oncology, Anti-viral and Metabolic Programs. That leverage our expertise in RNA interference (RNAi). Therapeutics and our Lipid Nanoparticle (LNP). View all ». Aug 7, 2015. Aug 5, 2015. View all ».

http://investor.arbutusbio.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.ARBUTUSBIO.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

December

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.9 out of 5 with 18 reviews
5 star
8
4 star
5
3 star
3
2 star
0
1 star
2

Hey there! Start your review of investor.arbutusbio.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.3 seconds

CONTACTS AT INVESTOR.ARBUTUSBIO.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Arbutus Biopharma - Investor Relations | investor.arbutusbio.com Reviews
<META>
DESCRIPTION
The Baruch S. Blumberg Institute. Surface Antigen Secretion Inhibitors. Oncology, Anti-virals and Metabolic Programs. RNAi Collaborators and Partners. HBV Collaborators and Partners. Arbutus Biopharma is a publicly-traded ( NASDAQ:TKMR. In addition to our HBV Assets. We are developing a pipeline of Oncology, Anti-viral and Metabolic Programs. That leverage our expertise in RNA interference (RNAi). Therapeutics and our Lipid Nanoparticle (LNP). View all ». Aug 7, 2015. Aug 5, 2015. View all ».
<META>
KEYWORDS
1 careers
2 news
3 about arbutus
4 overview
5 management
6 our board
7 current opportunities
8 about hbv
9 hbv background
10 hbv science
CONTENT
Page content here
KEYWORDS ON
PAGE
careers,news,about arbutus,overview,management,our board,current opportunities,about hbv,hbv background,hbv science,about rnai,rna interference,lnp delivery platform,mrna,rna trigger technologies,r&d portfolio,hbv assets,tkm hbv,tlr 9 agonist,tkm plk1
SERVER
Microsoft-IIS/6.0
POWERED BY
ASP.NET
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Arbutus Biopharma - Investor Relations | investor.arbutusbio.com Reviews

https://investor.arbutusbio.com

The Baruch S. Blumberg Institute. Surface Antigen Secretion Inhibitors. Oncology, Anti-virals and Metabolic Programs. RNAi Collaborators and Partners. HBV Collaborators and Partners. Arbutus Biopharma is a publicly-traded ( NASDAQ:TKMR. In addition to our HBV Assets. We are developing a pipeline of Oncology, Anti-viral and Metabolic Programs. That leverage our expertise in RNA interference (RNAi). Therapeutics and our Lipid Nanoparticle (LNP). View all ». Aug 7, 2015. Aug 5, 2015. View all ».

INTERNAL PAGES

investor.arbutusbio.com investor.arbutusbio.com
1

Arbutus Biopharma - Board of Directors

http://investor.arbutusbio.com/directors.cfm

The Baruch S. Blumberg Institute. RNAi Collaborators and Partners. HBV Collaborators and Partners. Dr Mark J. Murray PhD. President and Chief Executive Officer. Herbert J. Conrad. Member of the Audit Committee. Member of the Corporate Governance and Nominating Committee. Chair of the Executive Compensation and Human Resources Committee. Richard C. Henriques. Chair of the Audit Committee. Member of the Executive Compensation and Human Resources Committee. Dr William T. Symonds PharmD.

2

Arbutus Biopharma - Email Alert Subscription

http://investor.arbutusbio.com/profile.cfm

The Baruch S. Blumberg Institute. RNAi Collaborators and Partners. HBV Collaborators and Partners. Step 1 of 3: Select Options. In light of Canada's anti-spam legislation (CASL) which came into effect on July 1, 2014, we are required to obtain your express consent to send you commercial electronic messages. If you wish to receive electronic communications from us, please indicate your consent by checking the boxes beside the materials that you wish to receive. Current Earnings and News.

3

Arbutus Biopharma - Financial Information

http://investor.arbutusbio.com/financials.cfm

The Baruch S. Blumberg Institute. RNAi Collaborators and Partners. HBV Collaborators and Partners. Here you will find a summary of Arbutus Biopharma's latest financial information. Third Quarter Financial Results. Nov 3, 2016. Aug 4, 2016. 2015 Annual Report (Form 10-K). Mar 11, 2016. Mar 9, 2016. Apr 8, 2016. Apr 8, 2016. Market Cap. (Mil). Share Related information provided by MorningStar, Inc. Data as of Nov 6, 2016. Add PDF file to Briefcase.

4

Arbutus Biopharma - Events & Presentations

http://investor.arbutusbio.com/eventdetail.cfm?EventID=163592

The Baruch S. Blumberg Institute. RNAi Collaborators and Partners. HBV Collaborators and Partners. Jefferies Hepatitis B Summit. Aug 6, 2015. Speaker: Dr. Mark Murray, Tekmira's President and CEO. Back to previous page.

5

Arbutus Biopharma - Investor Relations

http://investor.arbutusbio.com/index.cfm

The Baruch S. Blumberg Institute. RNAi Collaborators and Partners. HBV Collaborators and Partners. Arbutus Biopharma is a publicly-traded ( NASDAQ:ABUS. View all ». Aug 10, 2016. Arbutus to Present at the 2016 Wedbush PacGrow Healthcare Conference. Aug 8, 2016. Arbutus Announces Issuance of Broad New US Patent for LNP Delivery Technology. View all ». Aug 16, 2016. 2016 Wedbush PacGrow Healthcare Conference. Jul 17, 2016. 2016 Controlled Release Society Conference. Partnering and Licensing Opportunities.

UPGRADE TO PREMIUM TO VIEW 12 MORE

TOTAL PAGES IN THIS WEBSITE

17

SOCIAL ENGAGEMENT



OTHER SITES

investor.aosmd.com investor.aosmd.com

Investor Overview | Alpha and Omega Semiconductor

Skip to main navigation. 31616;体中&#25991. Powering a Greener Future ™. Investor Information and Tools. Alpha and Omega Semiconductor Limited, or AOS, is a designer, developer and global supplier of a broad range of power semiconductor products. AOS has developed extensive intellectual property and technical knowledge that encompasses the latest advancements in the power semiconductor industry, which enables us to introduce innovative products to address the increasingly complex power requirements of adva...

investor.aosmith.com investor.aosmith.com

Investor Relations - A.O. Smith Corporation

Looking for a water heater? July 23, 2015. A O Smith reports record earnings on strong global sales growth; raises full year EPS guidance over 10 percent. July 1, 2015. A O Smith to hold second quarter conference call on July 23. View all financial releases ». August 13, 2015. 2015 Summer Investor Presentation. July 23, 2015 at 10:00 AM ET. Second Quarter 2015 Earnings Call. May 27, 2015. Spring 2015 Investor Presentation. View all events and presentations ». A O Smith Water Heaters: See How They're Made.

investor.appliedmicro.com investor.appliedmicro.com

AppliedMicro - Powering Your Cloud Network - Investor Relations - Investor Relations

Applied Micro Circuits Corporation at Oppenheimer Technology, Internet and Communications Conference. 160;at 10:25 am ET. Applied Micro Circuits Corporation at Oppenheimer Technology, Internet and Communications Conference. Wednesday, August 12, 2015 . 10:25 am ET  . Click here for webcast. Click here to add this event to your calendar. Applied Micro Circuits Corporation at Canaccord Genuity Growth Conference. 160;at 11:00 am ET. Applied Micro Circuits Corporation at Canaccord Genuity Growth Conference.

investor.aqxpharma.com investor.aqxpharma.com

Investor Relations - Aquinox Pharmaceuticals, Inc

Activate excellence. Activate innovation. Activate success. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Aquinox Pharmaceutical Inc's financial performance into perspective. Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC and Reports Second Quarter 2015 Financial Results. View all press releases ». 8/13/15 at 3:00 PM ET.

investor.aradigm.com investor.aradigm.com

Investor Relations | Aradigm Corporation

Skip to main navigation. Mar 29, 2018. Transfer Agent and Registrar. Communications concerning stock transfer requirements, lost certificates and change of address should be directed to:. Shareholder correspondence should be mailed to:. College Station, TX 77842-3170. Overnight correspondence should be sent to:. 211 Quality Circle, Suite 210. College Station, TX 77845. Https:/ www-us.computershare.com/investor/Contact. Mar 23, 2018. Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results.

investor.arbutusbio.com investor.arbutusbio.com

Arbutus Biopharma - Investor Relations

The Baruch S. Blumberg Institute. Surface Antigen Secretion Inhibitors. Oncology, Anti-virals and Metabolic Programs. RNAi Collaborators and Partners. HBV Collaborators and Partners. Arbutus Biopharma is a publicly-traded ( NASDAQ:TKMR. In addition to our HBV Assets. We are developing a pipeline of Oncology, Anti-viral and Metabolic Programs. That leverage our expertise in RNA interference (RNAi). Therapeutics and our Lipid Nanoparticle (LNP). View all ». Aug 7, 2015. Aug 5, 2015. View all ».

investor.archcoal.com investor.archcoal.com

Arch Coal, Inc. | Investors: Investor Relations Home

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Arch Coal's performance into perspective. Arch Coal is listed on the New York Stock Exchange (NYSE: ACI) and maintains its corporate headquarters in St. Louis, Mo. Arch Coal, Inc. Reports Second Quarter 2015 Results. Supplemental Historical Information Regional Realization and Cost Analysis. 2014 Annual Report Narrative. Or www.amstock.com.

investor.ariad.com investor.ariad.com

ARIAD Pharmaceuticals, Inc: Investor home

Our Name and Logo. Our Vision, Mission and Values. Our Vision, Mission and Values. Key to long-term value: discipline, execution and consistent communication. ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer an...

investor.arinet.com investor.arinet.com

Investors — Investor Information - ARI

ARI - We Create Connections. ARI has helped us support the 9 manufacturer brands we sell which has been. Essential to our growth. Our OEM part sales are up 265%. From last year.". Mdash; Powersports Dealer. Services for the Powersports industry. Up-to-date information from all of my manufacturers is critical to my business. Working with ARI saves us more than $450 per week. In outsourcing fees while growing my parts business by 125%. Mdash; OPE Dealer. Services for the Outdoor Power Equipment industry.

investor.aripaev.ee investor.aripaev.ee

AP investor

LHV Maailma Aktsiad Fond A. LHV Maailma Aktsiad Fond B. Nordea Pensionifond Aktsiad 100. Danske Pension 100 Pluss. Mandatum Life Indonesia Index. Mandatum Life Australia Index. Mandatum Life Russia Index. Mandatum Life Brazil Index. Mandatum Life India Index. Hetkel tehinguid sooritatud pole. Nordea Pensionifond A Pluss. NASDAQ OMX Tallinna, Riia ja Vilniuse börsiinfo 15 minutilise viivisega. Info uuendamiseks kasuta "uuenda/refresh" nuppu lehe pealkirja vasakus servas.

investor.arlp.com investor.arlp.com

Alliance Resource Partners, L.P. »Overview

Safety and Technology  . Mines and Facilities  . Community Involvement  . Alliance in the Community. Career Opportunities  . Investor Relations  . About Us  . Coal: Fuel for Economic Growth. Alliance Resource Partners, L.P. Guidance Update. 160;at 11:00 am ET. Alliance Resource Partners, L.P. Guidance Update. Monday, August 3, 2015 . 11:00 am ET  . Click here for webcast. Second Quarter 2015 Alliance Resource Partners, L.P. and Alliance Holdings GP, L.P. Earnings Conference Call. 160;at 9:00 am ET. Repli...